3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 3
3
Phase 1
2
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
1
Dermatologic
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
fludarabine phosphate
5
Cyclophosphamide
5
Azacitidine
4
Thiotepa
3
Stem Cell Transplantation
3
Melphalan
3
Gemtuzumab
3
Decitabine
3
Cytarabine
3
Busulfan
3
venetoclax
2
Radiotherapy
2
Methylprednisolone
2
Interferon alpha-2
2
Injections
2
Filgrastim
2
Etoposide
2
Emapalumab
2
Cyclosporine
2
Cladribine
2
Antilymphocyte Serum
2
vosaroxin
1
vedolizumab
1
trametinib
1
tipifarnib
1
thymoglobulin
1
peginterferon alfa-2b
1
peginterferon alfa-2a
1
nilotinib
1
midostaurin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
peginterferon alfa-2b
×
Myeloid
×
Clear all
NCT03547154
2019-08-12
C98026
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
344 enrolled
11 charts